Heemann U W, Azuma H, Tullius S G, Schmid C, Philipp T, Tilney N L
Department of Nephrology, University Hospital Essen, Germany.
Clin Nephrol. 1996 Jul;46(1):34-8.
The etiology of chronic rejection of kidney allografts is unknown, although hyperfiltration, acute rejection, viral infection and initial graft ischemia have been implicated. To test whether endothelial activation may be the link between these factors and chronic rejection, the endotoxin (lipopolysaccharide-LPS), a potent activator of endothelial cells, was evaluated in an established chronic rejection model. Bilaterally nephrectomized Lewis recipients of orthotopically transplanted Fisher 344 kidneys were treated briefly with low dose cyclosporine (1.5 mg/kg/day x 10). Recipients were given a non-lethal dose of LPS (2 mg) i.p. at 8 weeks and compared to allografted controls treated with vehicle. Urine protein was measured every 4 weeks. Rats in the treated group were sacrificed at 12 and 16 weeks, control animals at 12, 16 and 24 weeks (20/group) and examined histologically. In the chronically rejecting control allografts, progressive interstitial and glomerular sclerosis and vascular intimal proliferation had become apparent by 12 weeks. Infiltration of glomeruli, particularly by macrophages (M phi), and the coincident presence of cytokines were prominent, peaking at 16 weeks. LPS treatment accelerated and intensified these changes; proteinuria was more pronounced (16 weeks: 79 mg/24 h vs. 49 mg/24 h, p < 0.05). Numbers of infiltrating M phi peaked at 12 weeks in LPS treated hosts (69 c/FV vs. 27 c/FV in untreated controls, p < 0.01), accompanied by an increased upregulation of MHC class II and cytokine expression, particularly TNF alpha and PDGF around arteries and areas of infiltration. BY 16 weeks, 35 +/- 3% of glomeruli in LPS treated recipients had become sclerotic vs. 15 +/- 6% (p < 0.05) in controls, again associated with increased expression of cytokines (PDGF, TNF alpha, TGF beta), adhesion molecules (ICAM-1) and extracellular matrix proteins. Overall, the extent of chronic rejection of grafts in LPS treated rats at 16 weeks was similar to that developing in non-treated rats at 24 weeks. Activation of graft endothelium and/or host leucocytes increased the pace of graft infiltration and the expression of cytokines and other molecules. These events accelerate the process of chronic rejection.
尽管超滤、急性排斥反应、病毒感染和初始移植肾缺血被认为与肾移植慢性排斥反应的病因有关,但其病因仍不清楚。为了检验内皮细胞活化是否可能是这些因素与慢性排斥反应之间的联系,在内毒素(脂多糖-LPS)(一种强力的内皮细胞激活剂)在已建立的慢性排斥反应模型中进行了评估。双侧肾切除的Lewis受体原位移植Fisher 344肾,用低剂量环孢素(1.5mg/kg/天×10)短期治疗。受体在第8周腹腔注射非致死剂量的LPS(2mg),并与用赋形剂治疗的同种异体移植对照组进行比较。每4周测量一次尿蛋白。治疗组大鼠在第12周和16周处死,对照组动物在第12周、16周和24周处死(每组20只),并进行组织学检查。在慢性排斥反应的对照同种异体移植中,到12周时,进行性间质和肾小球硬化以及血管内膜增殖已经很明显。肾小球浸润,特别是巨噬细胞(M phi)浸润,以及细胞因子的同时存在很突出,在16周时达到峰值。LPS治疗加速并加剧了这些变化;蛋白尿更明显(16周时:79mg/24小时对49mg/24小时,p<0.05)。在LPS治疗的宿主中,浸润的M phi数量在12周时达到峰值(69个/视野对未治疗对照组的27个/视野,p<0.01),同时伴随着MHC II类和细胞因子表达的上调增加,特别是在动脉周围和浸润区域的TNFα和PDGF。到16周时,LPS治疗受体中35±3%的肾小球发生硬化,而对照组为15±6%(p<0.05),同样与细胞因子(PDGF、TNFα、TGFβ)、黏附分子(ICAM-1)和细胞外基质蛋白的表达增加有关。总体而言,LPS治疗大鼠在16周时移植物慢性排斥反应的程度与未治疗大鼠在24周时的程度相似。移植物内皮细胞和/或宿主白细胞的活化增加了移植物浸润的速度以及细胞因子和其他分子的表达。这些事件加速了慢性排斥反应的进程。